Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy

Citations Over TimeTop 10% of 2015 papers

Abstract

Alzheimer disease (AD) represents a major medical problem where mono-therapeutic interventions demonstrated only a limited efficacy so far. We explored the possibility of developing a combinational therapy that might prevent the degradation of neuronal and endothelial structures in this disease. We argued that the distorted balance between excitatory (glutamate) and inhibitory (GABA/glycine) systems constitutes a therapeutic target for such intervention. We found that a combination of two approved drugs - acamprosate and baclofen - synergistically protected neurons and endothelial structures in vitro against amyloid-beta (Aβ) oligomers. The neuroprotective effects of these drugs were mediated by modulation of targets in GABA/glycinergic and glutamatergic pathways. In vivo, the combination alleviated cognitive deficits in the acute Aβ25-35 peptide injection model and in the mouse mutant APP transgenic model. Several patterns altered in AD were also synergistically normalised. Our results open up the possibility for a promising therapeutic approach for AD by combining repurposed drugs.

Related Papers

• → Glutamatergic neurotransmission in aging: a critical perspective(2001)376 cited
• → Repeated Restraint Stress Alters Hippocampal Glutamate Uptake and Release in the Rat(2004)73 cited
• → Monitoring extracellular glutamate in hippocampal slices with a microsensor(2006)35 cited
• → The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease(2004)37 cited
• → Anatomy of Putative Glutamatergic Neurons(1988)57 cited